NYSE - Delayed Quote USD

Elanco Animal Health Incorporated (ELAN)

Compare
17.88 -0.47 (-2.56%)
At close: June 12 at 4:00 PM EDT
17.99 +0.11 (+0.62%)
After hours: June 12 at 7:34 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
4,365,000.00
4,417,000.00
4,411,000.00
4,764,000.00
3,271,000.00
--
Cost of Revenue
1,952,000.00
1,931,000.00
1,913,000.00
2,132,000.00
1,667,000.00
--
Gross Profit
2,413,000.00
2,486,000.00
2,498,000.00
2,632,000.00
1,604,000.00
--
Operating Expense
2,175,000.00
2,160,000.00
2,114,000.00
2,328,000.00
1,686,000.00
--
Operating Income
238,000.00
326,000.00
384,000.00
304,000.00
-82,000.00
--
Net Non Operating Interest Income Expense
-279,000.00
-277,000.00
-241,000.00
-236,000.00
-150,000.00
--
Other Income Expense
-1,250,000.00
-1,244,000.00
-215,000.00
-639,000.00
-445,000.00
--
Pretax Income
-1,291,000.00
-1,195,000.00
-72,000.00
-571,000.00
-677,000.00
--
Tax Provision
11,000.00
36,000.00
6,000.00
-88,000.00
-103,000.00
--
Net Income Common Stockholders
-1,302,000.00
-1,231,000.00
-78,000.00
-483,000.00
-574,000.00
--
Diluted NI Available to Com Stockholders
-1,302,000.00
-1,231,000.00
-78,000.00
-483,000.00
-574,000.00
--
Basic EPS
-2.65
-2.50
-0.16
-0.99
-1.30
--
Diluted EPS
-2.65
-2.50
-0.16
-0.99
-1.30
--
Basic Average Shares
492,825.00
492,300.00
488,300.00
487,200.00
441,400.00
--
Diluted Average Shares
493,100.00
492,300.00
488,300.00
487,200.00
441,400.00
--
Total Expenses
4,127,000.00
4,091,000.00
4,027,000.00
4,460,000.00
3,353,000.00
--
Net Income from Continuing & Discontinued Operation
-1,302,000.00
-1,231,000.00
-78,000.00
-483,000.00
-574,000.00
--
Normalized Income
-597,000.00
-307,490.00
66,570.00
53,290.72
-44,450.00
--
Interest Expense
279,000.00
277,000.00
241,000.00
236,000.00
150,000.00
--
Net Interest Income
-279,000.00
-277,000.00
-241,000.00
-236,000.00
-150,000.00
--
EBIT
-1,012,000.00
-918,000.00
169,000.00
-335,000.00
-527,000.00
--
EBITDA
-325,000.00
-224,000.00
851,000.00
381,000.00
-10,000.00
--
Reconciled Cost of Revenue
1,812,000.00
1,785,000.00
1,759,000.00
1,972,000.00
1,510,000.00
--
Reconciled Depreciation
687,000.00
694,000.00
682,000.00
716,000.00
517,000.00
--
Net Income from Continuing Operation Net Minority Interest
-1,302,000.00
-1,231,000.00
-78,000.00
-483,000.00
-574,000.00
--
Total Unusual Items Excluding Goodwill
-1,175,000.00
-1,169,000.00
-183,000.00
-634,000.00
-623,000.00
--
Total Unusual Items
-1,175,000.00
-1,169,000.00
-183,000.00
-634,000.00
-623,000.00
--
Normalized EBITDA
850,000.00
945,000.00
1,034,000.00
1,015,000.00
613,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-470,000.00
-245,490.00
-38,430.00
-97,709.28
-93,450.00
--
12/31/2019 - 9/20/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ZTS Zoetis Inc.
175.85
-1.51%
 
PETQ PetIQ, Inc.
22.26
+0.82%
 
AMRX Amneal Pharmaceuticals, Inc.
7.11
+1.14%
 
CTLT Catalent, Inc.
55.95
+0.25%
 
PAHC Phibro Animal Health Corporation
17.78
+6.15%
 
BHC Bausch Health Companies Inc.
6.31
+3.44%
 
TAK Takeda Pharmaceutical Company Limited
13.34
0.00%
 
VTRS Viatris Inc.
10.63
-0.09%
 
HLN Haleon plc
8.32
0.00%
 
EBS Emergent BioSolutions Inc.
6.32
-2.47%